Last reviewed 2026-04-22 · How we verify

OAC + clopicogrel

OAC (oral anticoagulant) combined with clopidogrel provides dual antiplatelet and anticoagulant therapy to prevent thrombotic events.

OAC (oral anticoagulant) combined with clopidogrel provides dual antiplatelet and anticoagulant therapy to prevent thrombotic events. Used for Acute coronary syndrome with indication for anticoagulation, Atrial fibrillation with acute coronary syndrome or percutaneous coronary intervention, Venous thromboembolism with concurrent acute coronary syndrome.

At a glance

Mechanism of action

This combination uses an oral anticoagulant (such as warfarin or a DOAC) to inhibit the coagulation cascade, while clopidogrel, a P2Y12 platelet receptor antagonist, prevents platelet aggregation. Together they provide complementary antithrombotic effects—anticoagulation plus antiplatelet activity—reducing risk of both arterial and venous thromboembolism in high-risk patients.

Approved indications

• Acute coronary syndrome with indication for anticoagulation
• Atrial fibrillation with acute coronary syndrome or percutaneous coronary intervention
• Venous thromboembolism with concurrent acute coronary syndrome

Common side effects

• Bleeding (major and minor)
• Gastrointestinal bleeding
• Intracranial hemorrhage
• Dyspepsia
• Bruising

Key clinical trials

• Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• OAC + clopicogrel CI brief — competitive landscape report
• OAC + clopicogrel updates RSS · CI watch RSS
• St. Antonius Hospital portfolio CI